Rigel Pharmaceuticals, Inc. Forecast, price target & analysts
Rigel Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Rigel Pharmaceuticals, Inc. Classifications & Recommendation:
Rigel Pharmaceuticals, Inc. Price Target
| Target Price | $32.00 |
| Price | $21.78 |
| Potential |
46.92%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Rigel Pharmaceuticals, Inc. 2026 .
The average Rigel Pharmaceuticals, Inc. target price is $32.00.
This is
46.92%
register free of charge
$57.00
161.71%
register free of charge
$20.00
8.17%
register free of charge
|
|
| A rating was issued by 6 analysts: 2 Analysts recommend Rigel Pharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rigel Pharmaceuticals, Inc. stock has an average upside potential 2026 of
46.92%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 116.88 | 171.80 |
| 2.79% | 46.98% | |
| EBITDA Margin | -16.47% | 9.89% |
| 62.80% | 160.05% | |
| Net Margin | -21.70% | 3.99% |
| 56.43% | 118.39% |
6 Analysts have issued a sales forecast Rigel Pharmaceuticals, Inc. 2024 . The average Rigel Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Rigel Pharmaceuticals, Inc. EBITDA forecast 2024. The average Rigel Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Rigel Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Rigel Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.44 | 0.39 |
| 57.65% | 127.08% | |
| P/E | 55.98 | |
| EV/Sales | 2.23 |
6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast for earnings per share. The average Rigel Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Rigel Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Rigel Pharmaceuticals, Inc....
Current Rigel Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 23 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 22 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 14 2025 |
| B. Riley Securities | Locked ➜ Locked | Locked | Dec 10 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Dec 10 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 10 2024 |
| B. Riley Securities | Locked ➜ Locked | Locked | Dec 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 22 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
B. Riley Securities: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
B. Riley Securities: Locked ➜ Locked
|
Dec 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
